News in Brief
This article was originally published in The Gold Sheet
FDA hits heparin supply chain; Ranbaxy consents to data integrity oversight; multinationals find solutions to China’s vaccine compendial crisis; EU seeks comment on safety measures, API imports.
You may also be interested in...
The European Union July 1 published its directive on falsified medicines, setting into motion a tightening of Europe’s pharmaceutical supply chain that will for the most part take place over the next 18 months – and that could cost pharmaceutical companies billions of Euros.
Recent GMP warning letters featured data integrity issues.